1,137 results on '"Graff‐Guerrero, Ariel"'
Search Results
2. Effect of personality traits, psychological resilience and life adversities on lifetime violence trajectories: A novel classification model in schizophrenia
3. Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study
4. The effect of second-generation antipsychotics on anxiety/depression in patients with schizophrenia: A systematic review and meta-analysis
5. Elevated intrinsic cortical curvature in treatment-resistant schizophrenia: Evidence of structural deformation in functional connectivity areas and comparison with alternate indices of structure
6. Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia
7. Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis
8. Lipopolysaccharide, Immune Biomarkers and Cerebral Amyloid-Beta Deposition in Older Adults With Mild Cognitive Impairment & Major Depressive Disorder
9. A Measure to Assess Illness Awareness in Problem Gambling: Gambling Awareness and Insight Scale (GAS)
10. Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
11. Evaluation of the Glymphatic System in Schizophrenia Spectrum Disorder Using Proton Magnetic Resonance Spectroscopy Measurement of Brain Macromolecule and Diffusion Tensor Image Analysis Along the Perivascular Space Index
12. 389. The Anxiolytic Effect of Atypical Antipsychotics in Patients With Schizophrenia: A Systematic Review and Meta-Analysis
13. 413. Identifying Predictors of Clozapine-Induced Weight Gain Through a Naturalistic Retrospective Chart Review
14. 390. Evaluation of the Glymphatic System in Schizophrenia Using 1H-MRS and MRI
15. Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels
16. Investigation of accelerated epigenetic aging in individuals suffering from schizophrenia in the context of lifetime suicide attempt
17. The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans
18. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies
19. Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
20. Patterns of functional connectivity alterations induced by alcohol reflect somatostatin interneuron expression in the human cerebral cortex
21. Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients
22. Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia
23. Childhood trauma exposure and personality traits in schizophrenia patients
24. A measure of subjective substance use disorder awareness – Substance Use Awareness and Insight Scale (SAS)
25. Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis
26. A measure of illness awareness in alcohol use disorder—Alcohol Use Awareness and Insight Scale (AAS)
27. Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia
28. Structural Brain Differences Between Cognitively Impaired Patients With and Without Apathy
29. Neurocognitive correlates of metabolic dysregulation in individuals with mood disorders: a systematic review and meta-analysis.
30. Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia
31. White matter microstructural organizations in patients with severe treatment-resistant schizophrenia: A diffusion tensor imaging study
32. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity
33. DAS: The Diabetes Awareness and Insight Scale
34. Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders
35. Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment
36. Comparing the distribution of neuropsychiatric symptoms among individuals with depression and mild cognitive impairment
37. Association between lipopolysaccharide, immune biomarkers and cerebral amyloid‐beta deposition in older adults with mild cognitive impairment & major depressive disorder
38. Disease Progression Patterns of Brain Morphology in Schizophrenia: More Progressed Stages in Treatment Resistance
39. Acetaldehyde‐mediated increase in glutamatergic and N‐acetylaspartate neurometabolite levels in the midcingulate cortex of ALDH2*1/*2 heterozygous young adults: A 1H‐MRS study with an alcohol clamp technique
40. Associations Between Structural Covariance Network and Antipsychotic Treatment Response in Schizophrenia
41. Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
42. Can we accurately classify schizophrenia patients from healthy controls using magnetic resonance imaging and machine learning? A multi-method and multi-dataset study
43. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study
44. Impaired Awareness of Problem and Pathological Gambling: A Review
45. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study
46. Resting-state functional connectivity in treatment response and resistance in schizophrenia: A systematic review
47. Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis
48. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study
49. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data
50. A meta-analysis of transcranial direct current stimulation for schizophrenia: “Is more better?”
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.